5-HT/CGRP pathway and Sumatriptan role in Covid-19

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Coronavirus disease 2019 (Covid-19), caused by SARS-CoV-2, involves immune cell hyperactivation and cytokine storm.
• Covid-19 can lead to central nervous system (CNS) injury, altering neurotransmitters like serotonin (5-HT) and CGRP.
• Elevated 5-HT and CGRP in Covid-19 may contribute to abnormal vascular reactivity and neuroinflammation.

Purpose of the Study:

• To explore the potential of Sumatriptan as a therapeutic agent for managing Covid-19.
• To investigate Sumatriptan's role in modulating 5-HT and CGRP pathways implicated in Covid-19 pathophysiology.

Main Methods:

• Review of Sumatriptan's pharmacological properties, including its action as a 5-HT receptor agonist and CGRP inhibitor.
• Analysis of the proposed mechanisms by which 5-HT and CGRP contribute to Covid-19-related inflammation and CNS effects.
• Evaluation of Sumatriptan's anti-inflammatory and antioxidant effects in the context of Covid-19 hyperinflammation.

Main Results:

• Sumatriptan's ability to inhibit 5-HT release and CGRP may counteract Covid-19-induced hyperinflammation.
• The drug's properties suggest a potential to mitigate CNS injury and abnormal vascular responses seen in Covid-19.
• Sumatriptan may reduce the pro-inflammatory cytokine release associated with Covid-19.

Conclusions:

• Sumatriptan presents a novel therapeutic strategy for Covid-19 management.
• Modulating 5-HT neurotransmitters and inhibiting CGRP with Sumatriptan could be effective in treating Covid-19.
• Sumatriptan's anti-inflammatory and antioxidant actions may alleviate Covid-19 hyperinflammation and its neurological sequelae.